[Production and characteristics of the growth and marker properties of mesenchymal stem cells of urinary bladder].
Zhidkova OV., Petrov NS., Popov BV.
Animal Study, published in Zh Evol Biokhim Fiziol (2013) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Zh Evol Biokhim Fiziol (2013)
- Country
- Russia (Federation)
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 23662484
Abstract (original English)
Mesenchymal stem cells (MSC) are capable for transdifferentiation into cells of another functional phenotype and are a perspective resourse of recovery therapy. MSC of different tissues differ by differentiation potential and in some cases express tissue-specific markers, which indicates close mesenchymal and parenchymal phenotypes of the same tissue. The homoorgan MSC might possibly be induced more effectively for tissue-specific differentiation and the preferred for cell therapy of diseases of the same organ as compared with widely used cells of the bone marrow origin. By using explants of the urinary bladder tissue, we obtained primary urinary bladder cell cultures of MSC of fetal and mature Balb/c mice (MSC-UBF and MSC-UBM) and characterized their properties in the course of long-term passing in culture. Unlike cells of mature animals, MSC-UBF have the steady capability for growth in vitro, clonogenic activity, and differentiation into adipose and bone cells. MSC-UBF express mesenchymal markers CD29, XD44, CD49f, CD90, and CD105, but not panleukocytic marker CD45, and do not differ by these parameters from the bone marrow MSC. Under normal conditions, MSC-UBF produce such urothelial markers as Ck14 and FOXA1, although their expression level is significantly lower than in the urinary bladder tissue. The hypomethylating reagent 5-azacytidin produces in MSC-UBF the expression
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.